Novel technique can potentially improve success of ovarian cancer treatment, study reveals

October 30, 2018

Novel Technique Can Potentially Improve Success of Ovarian Cancer Treatment, Study Reveals

Instead of destroying a tumour's blood supply, a first-ever University of Guelph study has proven that opening up the vessels is potentially more effective when it comes to fighting ovarian cancer.

This is because open vessels provide a clear pathway for treatment to attack the tumour.

"There hasn't been much hope for women with ovarian cancer," said Prof. Jim Petrik, lead author of the ground-breaking study. "What we are working on has never been done before and it has the potential to make a significant impact on effective treatment."

Published recently in the journal Clinical Cancer Research, the study is the first to investigate the impact of establishing a healthy blood supply to the tumour prior to treatment in mice models with an advanced stage of ovarian cancer.

Current treatment has focused on destroying all the blood vessels and starving the tumour, but it has had poor success, said Petrik.

"When you cut off a tumour's blood supply it often becomes more aggressive," he said. "We developed an approach where you only kill off the dysfunctional blood vessels. The result is a smaller, calmer tumour with a good blood supply. Once you have established an effective vascular system, you can use that system to get treatment to the tumour."

The study was conducted on mice models with an advanced stage of ovarian cancer because this type of cancer often goes undetected until the late stages when survival is low. The current mortality rate for ovarian cancer is 80 per cent.

The first step was to prune the blood vessels supplying the tumour. Tumours grow at an intense rate and this rapid growth results in a vast, yet dysfunctional, blood supply. Once a smaller, healthier blood supply to the tumour was created, the mice were then treated with an oncolytic virus. This novel treatment uses viruses to infect and kill cancer cells and also stimulate anti-tumour responses in the body.

"Using an oncolytic virus to treat ovarian cancer is currently underway in human clinical trials, but the success rate is very low. It's difficult to get the virus to the tumour because of its dysfunctional vascular system."

By pruning the vessels to create a normal blood supply to the tumour, Petrik was able to dramatically increase the uptake and activity of the virus.

"Using this combination of treatment we saw the tumour regress from an advanced state, but even more importantly we eradicated the spread of the cancer cells," said Petrik. "With this type of cancer, the tumour will grow in the ovary to a large size and then typically spread to the abdomen causing perforation of the gut or sepsis. Women die from the metastatic nature of the disease not from the tumour."

Targeting the tumour's blood supply and improving it rather than destroying it could also help other treatments, including chemotherapy, which are delivered through the vascular system, he added.

"The treatment for ovarian cancer hasn't really progressed in four decades. There are limited therapeutic advances, but these findings show that we may be able to improve the effectiveness of our current treatments if we improve the delivery system."
-end-
Contact

Prof. Jim Petrik
jpetrik@uoguelph.ca

University of Guelph

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.